Trade Summary

3 days ago, Goeltz II Robert C., serving as CFO at Arcus Biosciences, Inc. (RCUS), sold 6,552 shares at $23.38 per share, for a total transaction value of $153,186.00. Following this transaction, Goeltz II Robert C. now holds 67,924 shares of RCUS.

This sale represents a 9.00% decrease in Goeltz II Robert C.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, December 31, 2025 and publicly disclosed via SEC Form 4 filing on Friday, January 2, 2026, 2 days after the trade was made.

Arcus Biosciences, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.